Literature DB >> 33654866

A PhoA-STII Based Method for Efficient Extracellular Secretion and Purification of Fab from Escherichia coli.

Ziyan Wang1, Yang Gao1, Manyu Luo1, Cedric Cagliero2, Hua Jiang2, Yueqing Xie2, Jianwei Zhu1,2, Huili Lu1.   

Abstract

In comparison with full-length IgGs, antigen binding fragments (Fabs) are smaller in size and do not require the complexed post-translational modification. Therefore, Fab can be cost-effectively produced using an Escherichia coli (E. coli) expression system. However, the disulfide-bonds containing exogenous protein, including Fab, tend to form insoluble inclusion bodies in E. coli, which has been the bottleneck for exogenous protein expressions using this system. The secretory expression of proteins in periplasm or extracellular medium are promising strategies to prevent the formation of inclusion bodies to improve the efficiency to produce Fabs from E. coli. The extracellular expression is of particularly interest since it releases the product into the medium, while periplasmic expression yield is limited to the periplasm space. In addition, the extracellular expression allows for the direct harvesting of proteins from the culture supernatant, sparing the procedures of cell lysis and reducing contamination of host cell protein or DNA. Using anti-VEGF Fab as an example, here we provide a protocol based on the alkaline phosphatase (phoA) promoter and the heat-stable enterotoxin II (STII) leader sequence. Using phosphate starvation to induce the secretory expression, the protocol could be generally used for the efficient production of Fabs.
Copyright © 2019 The Authors; exclusive licensee Bio-protocol LLC.

Entities:  

Keywords:  Extracellular production; Fab; PhoA; STII; Secretion

Year:  2019        PMID: 33654866      PMCID: PMC7854137          DOI: 10.21769/BioProtoc.3370

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  12 in total

Review 1.  Post-translational modifications in the context of therapeutic proteins.

Authors:  Gary Walsh; Roy Jefferis
Journal:  Nat Biotechnol       Date:  2006-10       Impact factor: 54.908

2.  Process for Continuous Fab Production by Digestion of IgG.

Authors:  Nicole Ulmer; Dragana Ristanovic; Massimo Morbidelli
Journal:  Biotechnol J       Date:  2019-07-24       Impact factor: 4.677

Review 3.  Microbial platform technology for recombinant antibody fragment production: A review.

Authors:  Sanjeev Kumar Gupta; Pratyoosh Shukla
Journal:  Crit Rev Microbiol       Date:  2016-07-07       Impact factor: 7.624

4.  A general platform for efficient extracellular expression and purification of Fab from Escherichia coli.

Authors:  Manyu Luo; Meiqi Zhao; Cedric Cagliero; Hua Jiang; Yueqing Xie; Jianwei Zhu; Hui Yang; Mengxiao Zhang; Ying Zheng; Yunsheng Yuan; Zixiu Du; Huili Lu
Journal:  Appl Microbiol Biotechnol       Date:  2019-03-18       Impact factor: 4.813

Review 5.  Genetic engineering modification and fermentation optimization for extracellular production of recombinant proteins using Escherichia coli.

Authors:  Yuling Zhou; Zhenghui Lu; Xiang Wang; Jonathan Nimal Selvaraj; Guimin Zhang
Journal:  Appl Microbiol Biotechnol       Date:  2017-12-21       Impact factor: 4.813

6.  Development of a high yielding E. coli periplasmic expression system for the production of humanized Fab' fragments.

Authors:  Mark Ellis; Pareshkumar Patel; Marjory Edon; Walter Ramage; Robert Dickinson; David P Humphreys
Journal:  Biotechnol Prog       Date:  2016-11-17

Review 7.  Bioprocessing of therapeutic proteins from the inclusion bodies of Escherichia coli.

Authors:  Amulya K Panda
Journal:  Adv Biochem Eng Biotechnol       Date:  2003       Impact factor: 2.635

8.  Cytosolic expression of functional Fab fragments in Escherichia coli using a novel combination of dual SUMO expression cassette and EnBase® cultivation mode.

Authors:  F Rezaie; F Davami; K Mansouri; S Agha Amiri; R Fazel; R Mahdian; N Davoudi; S Enayati; M Azizi; V Khalaj
Journal:  J Appl Microbiol       Date:  2017-06-09       Impact factor: 3.772

Review 9.  The Clinical Effectiveness of Ranibizumab Treat and Extend Regimen in nAMD: Systematic Review and Network Meta-Analysis.

Authors:  Andriy Danyliv; Julie Glanville; Rachael McCool; Alberto Ferreira; Adrian Skelly; Ruth Pulikottil Jacob
Journal:  Adv Ther       Date:  2017-02-10       Impact factor: 3.845

10.  SHuffle, a novel Escherichia coli protein expression strain capable of correctly folding disulfide bonded proteins in its cytoplasm.

Authors:  Julie Lobstein; Charlie A Emrich; Chris Jeans; Melinda Faulkner; Paul Riggs; Mehmet Berkmen
Journal:  Microb Cell Fact       Date:  2012-05-08       Impact factor: 5.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.